Fredun Pharmaceuticals P/E Ratio
FREDUN • P/E ratio trend, valuation band, and sector comparison — all formatted to support journal-based trading review.
Current P/E Ratio
37.29
High Valuation
Very High - High growth expectations or significantly overvalued
Current Valuation Metrics
P/E Ratio
37.29
Current Price
₹1671.80
EPS (TTM)
₹44.83
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
47.23
Sector Median
26.0
Sector Rank
#11 of 140
Sector Percentile
7.9%
Earnings Breakdown (TTM)
TTM EPS
₹76.11
Sept 2025
₹19.98
Mar 2025
₹12.71
Key P/E Ratio Insights for Fredun Pharmaceuticals
- Stock appears overvalued with PE of 37.29, suggesting caution for new investments
- Trading at discount to sector average PE of 47.23
Related Pages for Fredun Pharmaceuticals
Additional stock information and data for FREDUN
Sector P/E Ratio Comparison
Comparing Fredun Pharmaceuticals with other companies in Healthcare sector
Sector Average
47.23
Sector Median
26.0
Lowest P/E
0.9
Highest P/E
898.7
Companies
140
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 0.9 | ₹31 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.48 | ₹1,128 | Low |
| Amwill Health Care | AMWILL | 5.98 | ₹61 | Low |
| Medicamen Organics | MEDIORG | 6.37 | ₹25 | Low |
| Brooks Laboratories | BROOKS | 6.41 | ₹127 | Low |
| Unichem Laboratories | UNICHEMLAB | 7.14 | ₹2,000 | Low |
| Zenith Drugs | ZENITHDRUG | 7.28 | ₹65 | Low |
| Galaxy Medicare | GML | 7.77 | ₹26 | Low |
| Vasundhara Rasayans | VRL | 9.19 | ₹34 | Low |